
Hester Biosciences Q2 FY27: consolidated PAT +44% YoY as EBITDA margin expands to 37%
Hester Biosciences' consolidated (primary) revenue came in at ₹97.91 Cr, up 38% YoY and 27% QoQ, with PAT of ₹20.63 Cr, up 44% YoY as reported (~41% on an adjusted basis stripping a minor ₹0.42 Cr exceptional gain this quarter — the year-ago quarter had no exceptional items, so the YoY comparison is largely clean). Standalone, the core India entity, posted revenue of ₹82.93 Cr (+28% YoY) and PAT of ₹16.66 Cr (+131% YoY). This is a micro-cap with no analyst consensus coverage located for this print, so street expectations are unknown rather than beaten or missed. The growth was margin-led as much as volume-led: standalone gross margin rose to 78% from 68% a year ago and EBITDA margin to 35% from 21%, which management attributes to a favourable product mix and cost discipline; consolidated EBITDA margin expanded to 37% from 33%. Poultry Healthcare (standalone) grew revenue 27% YoY on institutional penetration and customer engagement, while Animal Healthcare grew 34% YoY in the quarter on tender execution — though H1 Animal Healthcare revenue is still down 14% YoY on a weak Q1 tender cycle, a seasonality/timing effect rather than demand loss. Management's own framing credits consolidated growth primarily to "the strong performance of the India business," with international operations "broadly stable." Management gave no formal FY27 revenue or margin guidance at the last concall and none accompanies this result either; that stance is unchanged. The headline QoQ swing — consolidated PAT down 79% from ₹96.73 Cr in Q1 FY27 — is not a deterioration: Q1's figure was inflated by an ₹85.77 Cr non-recurring gain after Hester Africa's loan with the Gates Foundation was amended (principal cut from USD 12 Mn to USD 5 Mn, accrued interest waived, remaining balance made interest-free), booked as an Ind AS 109 extinguishment gain. Stripped of that, Q2's underlying consolidated performance is a sequential improvement, not a decline. Alongside results, the board approved a fresh unsecured USD 1 Mn loan to Hester Africa (9% interest, 3-year tenure) and the company completed divestment of its remaining 11% stake in Texas Lifescience Pvt Ltd, concluding the partial exit begun with last year's 43.81% stake sale. Going into Q3, the "Way Forward" section repeats existing priorities — poultry growth, Animal Healthcare portfolio refinement, vaccine/regulatory pipeline progress (including PPR, Goat Pox, and export registrations), manufacturing efficiency, and export market development — without new numeric targets, consistent with management's prior refusal to commit to specific FY27 figures.
Key Highlights
- Consolidated revenue ₹97.91 Cr, +38% YoY, +27% QoQ, led by India poultry (+27% YoY) and tender-driven animal healthcare (+34% YoY)
- Consolidated PAT ₹20.63 Cr, +44% YoY reported (~+41% adjusted); standalone PAT ₹16.66 Cr, +131% YoY on revenue ₹82.93 Cr (+28% YoY)
- Consolidated EBITDA margin 37% vs 33% a year ago; standalone EBITDA margin 35% vs 21%, gross margin 78% vs 68%
- QoQ PAT fell 79% from ₹96.73 Cr in Q1 FY27 — that figure included an ₹85.77 Cr one-time gain from Hester Africa's Gates Foundation loan modification (USD 12 Mn principal cut to USD 5 Mn, interest waived); not a sign of weakness
- Board approved a fresh unsecured USD 1 Mn loan to Hester Africa at 9% interest, 3-year tenure
- Company completed divestment of its remaining 11% stake in Texas Lifescience Pvt Ltd (TLPL) during the quarter
- No formal FY27 guidance reiterated; H1 Animal Healthcare revenue still down 14% YoY on weak Q1 tender timing
Price Impact
More from HESTERBIO